Merck & Co., Inc.

NYSE MRK

Merck & Co., Inc. Price to Sales Ratio (P/S) on January 14, 2025: 3.99

Merck & Co., Inc. Price to Sales Ratio (P/S) is 3.99 on January 14, 2025, a -20.06% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.
  • Merck & Co., Inc. 52-week high Price to Sales Ratio (P/S) is 5.55 on March 28, 2024, which is 39.30% above the current Price to Sales Ratio (P/S).
  • Merck & Co., Inc. 52-week low Price to Sales Ratio (P/S) is 3.85 on November 15, 2024, which is -3.35% below the current Price to Sales Ratio (P/S).
  • Merck & Co., Inc. average Price to Sales Ratio (P/S) for the last 52 weeks is 4.82.
Key data
Date Price to Sales Ratio (P/S) Price to Book Ratio (P/B) Dividend Yield Free Cash Flow Yield
Market news
Loading...
NYSE: MRK

Merck & Co., Inc.

CEO Mr. Robert M. Davis J.D.
IPO Date Jan. 13, 1978
Location United States
Headquarters 2000 Galloping Hill Road
Employees 70,000
Sector Health Care
Industries
Description

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Similar companies

BMY

Bristol-Myers Squibb Company

USD 55.74

0.69%

PFE

Pfizer Inc.

USD 26.41

-1.46%

LLY

Eli Lilly and Company

USD 744.91

-6.59%

JNJ

Johnson & Johnson

USD 144.75

0.19%

ABBV

AbbVie Inc.

USD 175.55

-0.67%

GILD

Gilead Sciences, Inc.

USD 91.00

1.18%

AMGN

Amgen Inc.

USD 267.10

-1.14%

StockViz Staff

January 15, 2025

Any question? Send us an email